- Home
- SBR vs AVBP Comparison
SBR vs AVBP Comparison
Compare SBR & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBR
- AVBP
- Stock Information
- Founded
- SBR 1982
- AVBP 2021
- Country
- SBR United States
- AVBP United States
- Employees
- SBR N/A
- AVBP N/A
- Industry
- SBR Oil & Gas Production
- AVBP
- Sector
- SBR Energy
- AVBP
- Exchange
- SBR Nasdaq
- AVBP NYSE
- Market Cap
- SBR 963.7M
- AVBP 879.2M
- IPO Year
- SBR N/A
- AVBP 2024
- Fundamental
- Price
- SBR $69.12
- AVBP $27.07
- Analyst Decision
- SBR
- AVBP Strong Buy
- Analyst Count
- SBR 0
- AVBP 4
- Target Price
- SBR N/A
- AVBP $38.00
- AVG Volume (30 Days)
- SBR 39.3K
- AVBP 152.0K
- Earning Date
- SBR 01-01-0001
- AVBP 03-04-2025
- Dividend Yield
- SBR 7.93%
- AVBP N/A
- EPS Growth
- SBR 5.15
- AVBP N/A
- EPS
- SBR 6.49
- AVBP N/A
- Revenue
- SBR $97,974,633.00
- AVBP N/A
- Revenue This Year
- SBR N/A
- AVBP N/A
- Revenue Next Year
- SBR N/A
- AVBP N/A
- P/E Ratio
- SBR $10.65
- AVBP N/A
- Revenue Growth
- SBR 4.88
- AVBP N/A
- 52 Week Low
- SBR $58.60
- AVBP $14.35
- 52 Week High
- SBR $70.20
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- SBR 60.48
- AVBP 49.67
- Support Level
- SBR $67.29
- AVBP $25.89
- Resistance Level
- SBR $69.00
- AVBP $28.12
- Average True Range (ATR)
- SBR 1.28
- AVBP 1.48
- MACD
- SBR 0.10
- AVBP -0.06
- Stochastic Oscillator
- SBR 78.09
- AVBP 33.69
About SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma and Texas.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.